BioNTech SE (NASDAQ:BNTX) shares are dropping Friday after the company announced it will terminate its Phase 2 clinical trial of autogene cevumeran in resected colorectal cancer. Here’s what you should know.
BioNTech stock is feeling bearish pressure. What’s behind BNTX decline?
BioNTech Ends Phase 2 Colorectal Cancer Trial
BioNTech is shutting down BNT122-01, a mid-stage study testing autogene cevumeran, its experimental personalized mRNA cancer treatment, as a solo therapy for patients whose colorectal cancer had been surgically removed but still showed circulating tumor DNA. Roche unit Genentech co-developed the treatment alongside BioNTech, and the two companies reached the termination decision together.
The trial had already tripped a futility threshold back in October 2025, but the study’s independent safety monitors felt the data was too premature at the time to draw firm conclusions, so BioNTech kept the trial running. A more recent review changed that: the safety board found a gap in overall survival between treated and untreated patients and concluded that continuing wouldn’t meaningfully change the outcome, leading it to recommend ending the study.
